



Innovative Technologies to Treat Diseases of the Back of the Eye

Guest Editors:

Prof. Dr. Rocio Herrero-Vanrell

Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain

Dr. Laurence Fitzhenry

Ocular Therapeutics Research Group, Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC), Department of Science, Waterford Institute of Technology, Waterford, Ireland

Deadline for manuscript submissions:

closed (31 May 2022)

Message from the Guest Editors

Dear Colleagues,

Delivering drugs targeted for posterior segment diseases of the eye in a safe, patient-friendly, and controlled manner has long been the focus of drug delivery researchers. With an aim to develop smart materials capable of the controlled release of ophthalmic drugs relevant in the treatment and management of back of the eye diseases, such research hopes to meet the challenges associated with the global rise in such diseases. Much of the focus has worked towards the development of both nanomaterial delivery carriers and extended-release platforms, such as nano- and micro-devices, implants and contact lenses, as effective means to bypass the ocular barriers and deliver drug efficiently to the posterior segment of the eye. All these innovative technologies are emerging as efficient therapeutic tools in the personalized treatment of back of the eye diseases. The development of animal models of posterior segment diseases is also a critical issue as most of these pathologies are chronic and multifactorial.

Prof. Dr. Rocio Herrero-Vanrell

Dr. Laurence Fitzhenry





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma